-+ 0.00%
-+ 0.00%
-+ 0.00%

Sionna Therapeutics Q3 2026 net loss widens 60% to $32.42 million

PUBT·11/10/2026 12:07:56
Listen to the news
Sionna Therapeutics Q3 2026 net loss widens 60% to $32.42 million
  • Sionna Therapeutics’ third-quarter 2026 net loss widened 60% year over year to $32.42 million.
  • Total operating expenses rose 46% year over year to $34.82 million.
  • Cash, cash equivalents and marketable securities totaled $249.8 million at September 30, 2026, expected to fund operations into second-half 2029.
  • The SION-451 + SION-2222 combination is expected to enter the AscenSION CF Phase 2 proof-of-concept trial in first-quarter 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sionna Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611100700PRIMZONEFULLFEED9873339) on November 10, 2026, and is solely responsible for the information contained therein.